Clarification Needed: Question Appears to Refer to Wrong Condition
The question asks about azithromycin dosing "post OGDS," but the provided evidence exclusively addresses gonococcal and chlamydial infections (oropharyngeal gonorrhea), not oesophagogastroduodenoscopy (OGDS/EGD), which is an endoscopic procedure.
If Asking About Oropharyngeal Gonorrhea Treatment:
For oropharyngeal gonococcal infection, azithromycin is NOT recommended as monotherapy due to antimicrobial resistance concerns, and current guidelines favor ceftriaxone monotherapy 1.
Current Treatment Recommendations:
Primary Treatment:
- Ceftriaxone 500 mg IM single dose (for patients <150 kg) is the first-line treatment for oropharyngeal gonorrhea 2, 3
- Azithromycin 2g orally as monotherapy is explicitly not recommended by CDC due to emerging macrolide resistance 1
When Azithromycin IS Used:
If chlamydial co-infection has not been excluded, add:
OR for chlamydia treatment specifically:
- Azithromycin 1g orally, single dose 1
Treatment Failure Scenarios:
If ceftriaxone treatment fails for oropharyngeal gonorrhea:
- Gentamicin 240 mg IM single dose PLUS azithromycin 2g orally single dose 4
- This combination is only for documented treatment failures, not initial therapy
Critical Caveats:
- The oropharynx is particularly problematic for gonorrhea treatment, with most ceftriaxone failures occurring at this site 4, 5
- Gentamicin and spectinomycin have poor pharyngeal efficacy 4
- Test-of-cure is mandatory for all pharyngeal gonorrhea cases 7-14 days post-treatment 3
- Azithromycin resistance rates are increasing globally, with high-level resistance (MIC ≥256 μg/mL) now documented 6, 7
If Actually Asking About Endoscopy Prophylaxis:
There is no indication for azithromycin prophylaxis after routine upper endoscopy (OGDS/EGD) in standard practice. The provided evidence does not support this use.